AdAlta (1AD) Investor presentation summary

Market opportunity and strategy

• Cellular immunotherapies present a major untapped opportunity in solid cancers, leveraging existing success in blood cancers and Asian innovation.

• The first clinical asset targets a $4B segment of the mesothelioma market with a first-in-class armoured CAR-T product.

• Business model focuses on capital efficiency, rapid innovation, and world-class manufacturing partnerships.

• Additional pipeline assets include a first-in-class anti-fibrotic protein and a pan-strain malaria inhibitor, both seeking strategic partners.

Barriers to CAR-T access

• Access to CAR-T therapies is limited by financial barriers such as reimbursement, high costs, and margin pressures.

• Operational barriers include complex supply chains, limited delivery capacity, and institutional constraints.

• Only a small fraction of eligible patients in developed markets receive CAR-T therapy due to these barriers.

• High total costs per patient ($500,000–$1M) and low gross margins compared to traditional therapies restrict broader adoption.

• Institutional limitations include lack of trained staff, facility capacity, and patient economic burden.

Solutions and enablers for improved access

• Designing products for access by enhancing efficacy, reducing adverse events, and enabling outpatient administration.

• Facilitating commercial product licensing to fill local pipeline gaps and replicate specialty pharma models.

• Leveraging Australia's clinical development ecosystem and incentives to attract global trials and early patient access.

• Supporting "home grown" CAR-T products through academic and hospital-based manufacturing, with regulatory and quality oversight.

• Implementing value chain enablers: regulatory flexibility, automation, education, and innovative reimbursement models.